The latest market report published by Credence Research,
Inc. “Global Hematopoietic
Stem Cells Transplantation Market –
Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 –
2022,” the hematopoietic stem cells transplantation market was valued
at USD 3,741.3 Mn in 2015, and is expected to reach USD 7,796.1 Mn by 2022,
expanding at a CAGR of 10.6% from 2016 to 2022.
Market Insights
Over 50 years of studies in the field of blood-forming stem
cells i.e. hematopoietic stem cells (HSC), researchers have developed
significant understanding to use HSCs as a therapy. At present, no type of stem
cell, adult, embryonic or fetal has attained such sufficient status.
Hematopoietic stem cell transplantation (HSCT) is now routinely used for
treating patients with malignant and non-malignant disorders of blood and the
immune system. Currently, researchers have observed that through animal studies
HSCs have the ability to form other cells such as blood vessels, muscles, and
bone. Further application of this approach it may eventually be able to treat a
wide array of conditions and replace ailing tissues. However, despite the vast
experience with HSCs, researchers face major barriers in expanding their use
beyond the replacement of immune and blood cells.
Browse the
full report Hematopoietic Stem Cells Transplantation Market – Growth,
Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report athttp://www.credenceresearch.com/report/hematopoietic-stem-cells-transplantation-market
Hematopoietic stem cells are unable to proliferate and
differentiate in-vitro. Researchers have yet to evolve an accurate method to
differentiate stem cells from other cells derived from blood or bone marrow.
Once such technical barriers are overcome, the avenues for realizing the full
potential of HSCT. The type of transplant a person receives depends on several
different factors, including the type and course of the disease, availability
of suitable donors, and the patient’s overall health. There are three different
sources of hematopoietic stem cells such as bone marrow, peripheral blood stem
cells, and umbilical cord blood. The stem cell source used for a given
transplant depends upon the underlying disease, the type of transplant
(allogeneic or autologous), and size of the patient.
Market Competition
Assessment:
The hematopoietic stem cells transplantation market is observed
as the most diversified and competitive market comprising large number of
players. The market is dominated by several players, depending on their
major competencies. The key players in this market are Kite Pharma Inc., Thermo
Fisher Scientific, PromoCell, CellGenix Technologie Transfer GmbH,
Cesca Therapeutics Inc., R&D Systems, Genlantis, Lonza Group Ltd.,
TiGenix N.V., and ScienCell Research Laboratories.
Request Free Sample : http://www.credenceresearch.com/sample-request/57984
Key Market Movements:
·
Rising prevalence of leukemia is expected to assist the
hematopoietic stem cells transplantation as the survival rates in leukemia
patients has been improved after HSCT.
·
Future opportunity for HSCT market lies in regenerative Stromal
Cell Therapy because it is considered as one of the novel therapies for
prevention and treatment of acute graft versus host disease in allogeneic HSCT
patients.
·
In emerging economies growing government support through
providing favorable environments for research laboratories in the field of stem
cell research
Blog : http://www.mobilecomputingtoday.co.uk/4174/global-hematopoietic-stem-cells-transplantation-market-expected-reach-usd-7796-1-2022-credence-research/
No comments:
Post a Comment